clinical trial · NCT05312879
Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1-Mediated Proteinuric Kidney Disease
Vertex Pharmaceuticals Incorporated·phase3·recruiting·n = 466
Proteinuric Kidney DiseaseVX-147Placebo
brief summary
The purpose of this study is to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of VX-147 in adult and pediatric participants with apolipoprotein L1 (APOL1)-mediated proteinuric kidney disease.
started
Mar 30, 2022
primary completion
Jun 2, 2028
completion
May 7, 2030
last updated
Apr 17, 2026
official title
A Phase 2/3 Adaptive, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VX-147 in Adult and Pediatric Subjects With APOL1-mediated Proteinuric Kidney Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol